Fundraising Fox

Oxalo Therapeutics

Chicago, US · Founded 2018 · Delaware corporation

oxalotherapeutics.com ↗

Oxalo Therapeutics is a preclinical-stage biopharmaceutical company developing therapies to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia, such as recurrent calcium oxalate kidney stones. Its microbiome-based approach mimics a natural mechanism using gut microbes to remove oxalate from the body.

BiotechHealthtech

Founders & leadership

Oxalo Therapeutics was founded in 2018 by Hatim Hassan.

HH
Hatim HassanCo-founder, R&D lead
YZ
Yang ZhengCo-founder, Business lead

Reported raises · per SEC filings

Form D private placements

$250K disclosed across 1 round · 2018

▶$250KraisedJun 2018 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang ZhengDirector
  • Hatim HassanExecutive Officer, Director
Amount sold
$250K
Minimum investment
$1
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Kidney5 shared keywordsThe National Kidney Foundation is a nonprofit organization focused on kidney disease, providing patient education, emotional support, and resources for patients, families, living donors, and transplant recipients. It advocates for kidney health policies and funds research and technology to improve early detection, treatment, and transplant access in the U.S.
Oup4 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Self Decode3 shared keywordsSelfDecode is a consumer genomics platform that analyzes users' DNA, blood test results, and lifestyle data to generate 1,500+ personalized health reports and AI-driven recommendations on diet, supplements, and lifestyle. It sells DNA test kits and subscription access to tools including an AI health assistant (DecodyGPT) and lab analysis, serving consumers, doctors, and businesses.
Fiveable3 shared keywordsFiveable provides AI-powered exam preparation for AP classes, offering practice questions with automated scoring and personalized study tools for high school students.

Companies competing with Oxalo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase IISTTR2022$1000K
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2019$2M
National Science FoundationPhase ISTTR2019$225K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2018$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Oxalo Therapeutics do?
Oxalo Therapeutics is a preclinical-stage biopharmaceutical company developing therapies to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia, such as recurrent calcium oxalate kidney stones. Its microbiome-based approach mimics a natural mechanism using gut microbes to remove oxalate from the body.
Who founded Oxalo Therapeutics?
Oxalo Therapeutics was founded by Hatim Hassan in 2018.
How much funding has Oxalo Therapeutics raised?
Oxalo Therapeutics has disclosed $250K raised across 1 round.
Where is Oxalo Therapeutics headquartered?
Oxalo Therapeutics is headquartered in Chicago, US.